MindBio Therapeutics Company Description

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia.

Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain.

MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.

MindBio Therapeutics Corp.

Country	Canada
Founded	2021
Industry	Biotechnology
Sector	Healthcare
CEO	Justin Hanka

Contact Details

Address: 1055 West Georgia Street Vancouver, British Columbia V6E 4N7 Canada
Website	mindbiotherapeutics.com

Stock Details

Ticker Symbol	MBIO
Exchange	Canadian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
SIC Code	2834

Key Executives

Name	Position
Justin Adam Hanka	Co Founder, Chief Executive Officer and Director
John M. Dinan	Chief Financial Officer
Dr. Lahiru Russell Ph.D.	Chief Scientist